Dark Forest Capital Management LP Sells 8,011 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Dark Forest Capital Management LP reduced its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 39.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,383 shares of the biopharmaceutical company’s stock after selling 8,011 shares during the quarter. Dark Forest Capital Management LP’s holdings in Ocular Therapeutix were worth $85,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in OCUL. Trust Co. of Vermont increased its position in shares of Ocular Therapeutix by 20.0% during the 4th quarter. Trust Co. of Vermont now owns 6,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,000 shares in the last quarter. Amalgamated Bank grew its stake in Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,481 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Ocular Therapeutix by 39.4% during the first quarter. Ameritas Investment Partners Inc. now owns 11,531 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 3,257 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Ocular Therapeutix by 36.9% in the second quarter. Victory Capital Management Inc. now owns 17,403 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 4,695 shares during the last quarter. Finally, Atlas Capital Advisors LLC acquired a new position in shares of Ocular Therapeutix in the 2nd quarter worth approximately $34,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Trading Up 0.2 %

Shares of OCUL opened at $8.70 on Tuesday. The stock’s fifty day simple moving average is $8.49 and its 200-day simple moving average is $7.38. The firm has a market capitalization of $1.35 billion, a PE ratio of -6.44 and a beta of 1.28. Ocular Therapeutix, Inc. has a 12-month low of $2.00 and a 12-month high of $11.31. The company has a quick ratio of 16.55, a current ratio of 16.64 and a debt-to-equity ratio of 0.18.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.04). The business had revenue of $16.40 million during the quarter, compared to the consensus estimate of $15.85 million. Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The firm’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same period last year, the business posted ($0.27) EPS. As a group, research analysts predict that Ocular Therapeutix, Inc. will post -1.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

OCUL has been the subject of a number of recent analyst reports. TD Cowen cut Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a report on Friday, June 21st. Robert W. Baird lowered their target price on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Piper Sandler reiterated an “overweight” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Friday, June 21st. Finally, HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.67.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.